



Market Announcement

11 June 2020

Proteomics International Laboratories Ltd (ASX: PIQ) – Trading Halt

Description

The securities of Proteomics International Laboratories Ltd ('PIQ') will be placed in trading halt at the request of PIQ, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 15 June 2020 or when the announcement is released to the market.

Issued by

Sean Maloney

Adviser, Listings Compliance (Perth)



Proteomics International

LABORATORIES LTD

11 June 2020

ASX Compliance Pty Ltd
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000
Attn: Madeleine Green

by email: tradinghaltspert@asx.com.au

Dear Ms Green

REQUEST FOR TRADING HALT

In accordance with ASX Listing Rule 17.1, Proteomics International Laboratories Ltd (ASX:PIQ) (the **Company**) requests a trading halt of its securities pending the release of an announcement of the results from the first stage collaborative study to target treatment of diabetic kidney disease (**DKD**) which will be presented and jointly delivered by Janssen Research & Development and Proteomics International at the world's leading diabetes conference, the 80th Scientific Sessions of the American Diabetes Association (**ADA**), on 13 June 2020 (10am US Central Time).

The Company requests the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the results from the collaborative study and the commencement of trading on Monday, 15 June 2020.

The Company is not aware of any reason why the request should not be granted, nor of any other relevant information in relation to this request.

Yours sincerely

Karen Logan
Company Secretary

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com